Figure 4: PMCA2 expression stratifies Basal breast cancers independent of TNBC subtypes. | Scientific Reports

Figure 4: PMCA2 expression stratifies Basal breast cancers independent of TNBC subtypes.

From: The calcium pump plasma membrane Ca2+-ATPase 2 (PMCA2) regulates breast cancer cell proliferation and sensitivity to doxorubicin

Figure 4

(A) Basal-like and Claudin-low breast cancers51 were assigned a TNBC subtype based on expression gene expression patterns from52; Basal-like Immune Activated (BLIA), Basal-like Immune Suppressed (BLIS), Luminal AR (LAR) and Mesenchymal (MES). (B) Distribution of TNBC-Subtypes in low and high expressing PMCA2 tumors and across all Basal-like and Claudin-low tumors. No significance was found between PMCA2 groupings via a χ2 test, P-value = 0.825. (C) Relapse-free-survival (RFS) for each of the TNBC-Subtypes compared to PMCA2 expression groupings. No significance was found between BLIA and BLIS tumors (Log-rank P-value 0.1488), however PMCA2 groupings were significant with a hazard ratio of 0.50 (95% CI 0.36 – 0.80) and P-value = 0.0024 comparing high expression to low.

Back to article page